Back to Search
Start Over
Treatment of refractory diffuse large B-cell lymphoma by chidamide combined with autologous stem cell transplantation: a case report.
- Source :
-
Anti-cancer drugs [Anticancer Drugs] 2021 Sep 01; Vol. 32 (8), pp. 886-889. - Publication Year :
- 2021
-
Abstract
- Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma, with certain DLBCLs affecting specific anatomic sites, such as primary cutaneous DLBCL, leg type and intravascular large B-cell lymphoma. However, the occurrence of secondary cutaneous involvement in DLBCL while patients are undergoing regular chemotherapy is rare. In this study, we reported a case of refractory diffuse large B-cell lymphoma with cutaneous involvement that achieved complete remission for more than 4 years with epigenetic regulation of chidamide in combination with chemotherapy and autologous hematopoietic stem cell transplantation including a pretreatment regimen containing chidamide.<br /> (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Subjects :
- Adult
Aminopyridines administration & dosage
Antineoplastic Agents administration & dosage
Benzamides administration & dosage
Combined Modality Therapy
Female
Humans
Lymphoma, Large B-Cell, Diffuse pathology
Lymphoma, Large B-Cell, Diffuse therapy
Aminopyridines therapeutic use
Antineoplastic Agents therapeutic use
Benzamides therapeutic use
Hematopoietic Stem Cell Transplantation methods
Lymphoma, Large B-Cell, Diffuse drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1473-5741
- Volume :
- 32
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Anti-cancer drugs
- Publication Type :
- Academic Journal
- Accession number :
- 34145178
- Full Text :
- https://doi.org/10.1097/CAD.0000000000001093